Companies › CLYD

CLYD 10-K & 10-Q changes, risk factors and insider trading

Beacon Topco, Inc. · Pharmaceutical Preparations · CIK 2094256 · All filings on SEC.gov

Everything below is quoted or computed from Beacon Topco, Inc.'s public SEC filings. It is not a recommendation to buy or sell. Automated comparisons can contain errors; confirm with the original filing.

At a glance

0Form 4 filings reporting open-market purchases (last 180 days)
0Form 4 filings reporting open-market sales (last 180 days)

Jump to: Annual report (10-K) · Quarterly report (10-Q) · Insider transactions · 13F holders

What changed in the latest 10-K

Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare..

What changed in the latest 10-Q

Comparing 10-Q filed 2026-07-14 (period ending 2026-06-30) with 10-Q filed 2026-06-05 (period ending 2026-03-31).

Risk Factors (10-Q Part II, Item 1A)

0new paragraphs
0removed paragraphs
0reworded paragraphs
68 → 68words in section

The section in the latest 10-Q reads in full:

During the period covered by this report, we did not conduct any significant activities other than those related to its formation and the matters contemplated by the Transactions. See “Cautionary Statement Regarding Forward Looking Statements” and “Risk Factors” in our Registration Statement on Form S-4 (File No. 333-291359) filed with and declared effective by the SEC on April 22, 2026, which is incorporated by reference herein.

No wording changes found in this section.

Full comparison: every changed paragraph (0)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Management's Discussion & Analysis (MD&A) (10-Q Part I, Item 2)

0new paragraphs
0removed paragraphs
1reworded paragraphs
354 → 354words in section
Full comparison: every changed paragraph (1)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Reworded

We are a Delaware corporation formed on September 24, 2025 as a wholly-owned subsidiary of Barinthus Biotherapeutics plc (“Barinthus Bio”) for purposes of consummating a business combination (the “Transactions”) with Barinthus Bio and Clywedog Therapeutics, Inc., a Delaware corporation (“Clywedog”). We have one wholly-owned direct subsidiary, Cdog Merger Sub, Inc. (“Merger Sub”), which is a Delaware corporation. We have not commenced operations and have not engaged in any significant activities other than those related to our formation from our incorporation on September 24, 2025 through MarchJune 31,30, 2026.

CLYD insider buying and selling (Form 4)

Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.

No Form 4 stock transactions in this period.

Well-known investors holding CLYD (13F)

None of the 59 investors we track reported a position in their latest 13F.

Coming soon: email alerts when CLYD files, watchlists and downloadable comparisons.